Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
68,022.49 +372.89 (+0.55%) CMC Crypto 200
1,430.03 +1.47 (+0.10%)
Quest Diagnostics Incorporated (DGX)
After hours:
| Previous close | 139.33 |
| Open | 139.58 |
| Bid | 140.14 x 900 |
| Ask | 140.15 x 1000 |
| Day's range | 139.39 - 142.06 |
| 52-week range | 119.59 - 145.62 |
| Volume | |
| Avg. volume | 975,377 |
| Market cap | 15.772B |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | 19.11 |
| EPS (TTM) | 7.43 |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 3.00 (2.11%) |
| Ex-dividend date | 08 Jul 2024 |
| 1y target est | 147.07 |
PR NewswireBlood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in JAMA Health Forum, a member of the JAMA Network. Researchers from Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of the Haystack MRD™ tumor-informed ctDNA MRD technology, City of Hope and the Walter and Eliza Hall Institute of Medical Research conducted
ZacksWhy Is Amedisys (AMED) Up 5.5% Since Last Earnings Report?
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksWhy Is Quest Diagnostics (DGX) Up 3.1% Since Last Earnings Report?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
